Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | SCN5A | Q14524 | 7/20 | 0.49 |
| ▸ | PIM1 | P11309 | 2/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.49 |
| ▸ | USP7 | Q93009 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | RBP4 | P02753 | 2/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1189278 | 0.98 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2KDM4EHSD17B10SCN5A | |
| SCHEMBL16154717 | 0.80 | PIM1 (0.50) | ALDH1A1SMN1; SMN2KDM4EHSD17B10SCN5A | |
| SCHEMBL11918906 | 0.76 | KDM4E (0.56) | ALDH1A1SMN1; SMN2KDM4EHSD17B10SCN5A | |
| SCHEMBL13687337 | 0.76 | SCN5A (0.50) | ALDH1A1SMN1; SMN2KDM4EHSD17B10SCN5A | |
| SCHEMBL17681362 | 0.72 | FGFR1 (0.58) | SCN5APIM1RETFGFR1FLT1 | |
| SCHEMBL11914744 | 0.72 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2KDM4EHSD17B10SCN5A | |
| SCHEMBL7699778 | 0.72 | SCN5A (0.50) | ALDH1A1SMN1; SMN2KDM4EHSD17B10SCN5A | |
| SCHEMBL19658993 | 0.72 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2KDM4EHSD17B10SCN5A | |
| SCHEMBL15898868 | 0.72 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2KDM4EHSD17B10SCN5A | |
| SCHEMBL18365954 | 0.71 | RBP4 (0.51) | ALDH1A1SMN1; SMN2KDM4EHSD17B10SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2240486-B1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, THEIR MANUFACTURE AND THEIR APPLICATION AS MEDICINE | SANOFI SA (FR) | 2015-09-09 | — | — | EP | disclosed |
| US-8853206-B2 | Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2014-10-07 | — | — | US | disclosed |
| US-20120208805-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| US-8198272-B2 | Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI-AVENTIS (FR) | 2012-06-12 | — | — | US | disclosed |
| US-20110034452-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| EP-2240486-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | Sanofi-Aventis (FR) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009097971-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208805-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL3, F2RL1 | ALDH1A1 2097/4885SMN1; SMN2 4840/4885KDM4E 3889/4885 |
| US-20110034452-A1 | TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL3, F2RL1 | ALDH1A1 2229/4885SMN1; SMN2 4842/4885KDM4E 3850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.